Anakinra and Kawasaki Disease

Phase 2 Completed 16 enrolled Assistance Publique - Hôpitaux de Paris Swedish Orphan Biovitrum · collab

NaSingle-groupOpen-labelTreatment

Summary

The study is designed to assess the efficacy and safety of anakinra, an interleukin 1 receptor antagonist, in patients with Kawasaki disease who failed to respond to standard treatment:e.g. one infusion of 2g/kg of intravenous immunoglobulins.

Timeline

Start: 2016-02-05
Primary completion: 2019-01-21
Completion: 2019-02-18

Publications

Kone-Paut I, Tellier S, Belot A, Brochard K, Guitton C, Marie I, Meinzer U, Cherqaoui B, Galeotti C, Boukhedouni N, Agostini H, Arditi M, Lambert V, Piedvache C. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease. Arthritis Rheumatol. 2021 Jan;73(1):151-161. doi: 10.1002/art.41481. Epub 2020 Nov 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anakinra	Protein / enzyme biologic	2 mg/kg	Subcutaneous
Subject	Anakinra	Protein / enzyme biologic	4 mg/kg	Subcutaneous
Subject	Anakinra	Protein / enzyme biologic	6 mg/kg	Subcutaneous
Subject	Anakinra	Protein / enzyme biologic	8 mg/kg	Subcutaneous

Anakinra and Kawasaki Disease

Summary

Timeline

Publications

Drugs

Indications